Imagine trying to build a complex Lego model where you have to stop and clean every single piece between steps; it takes forever. This project creates a 'chemical assembly line' that combines several steps into one smooth flow. It specifically helps make rare amino acids, which are like the essential custom bricks needed for advanced medicines.
Producing non-natural amino acids with two stereocenters is currently inefficient and slow, often requiring 8-step processes. This creates supply chain bottlenecks for critical drugs like Paxlovid™.
A 3-step stereoselective synthesis process for amino acids (specifically isoleucine) using biocatalysis and flow chemistry at TRL 6.
If you are a drug manufacturer dealing with the high cost and complexity of peptide-based drugs like Paxlovid™ — this project developed a 3-step synthesis that replaces an 8-step process. This significantly reduces production time and waste.
If you are a chemical provider dealing with the inability to scale non-natural amino acids with two stereocenters — this project developed a modular technology platform. It allows you to produce a wide range of different amino acids by simply changing the starting product.
If you are a biotech firm dealing with the scarcity of high-demand isoleucine isomers for antibiotics — this project developed a TRL 6 process. This enables a direct-to-market supply chain for these critical building blocks.
Based on available project data, the process reduces the synthetic route from 8 steps to 3 steps, which typically lowers labor, time, and material costs.
Yes, the project aims to reach TRL 6 and utilizes flow chemistry and reaction engineering expertise from SMEs ChiralVision and SpinChem to ensure scalability.
Based on available project data, the technology builds on the previous ONE-FLOW project, but specific licensing terms for cassaFLOW are not provided.
The project uses flow technology to telescope reaction paths, meaning it replaces multiple separate work-up steps with a continuous, shorter process.
The project runs from 2024-01-01 to 2026-12-31, aiming for a TRL 6 outcome that can be directly placed on the market.
The consortium is well-balanced for commercialization, featuring a 40% industry ratio with 2 SMEs (ChiralVision and SpinChem) and 3 universities across 3 countries (DE, NL, SE). This structure ensures that academic research from TU Delft is immediately paired with reaction engineering and commercial expertise to move the technology from lab to market.
Contact the Technical University of Delft (TU Delft) regarding the cassaFLOW project.
Contact us to identify licensing opportunities for this TRL 6 amino acid platform.
